ALX also affected CML stem/progenitor cells that represent a clinical issue as they are resistant to Tyrosine Kinase Inhibitors (TKIs) that target the BCR::ABL1 oncogenic driver of CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.